Haemonetics (HAE) Director Ellen M. Zane Receives RSU Award

What Happened
Ellen M. Zane (listed in the filing as Zane Ellen M), a director of Haemonetics Corporation, was granted 2,538 restricted stock units (RSUs) on July 24, 2026. The Form 4 reports this as an award (code A); no per-share price or immediate cash value is provided. Per the filing, the RSUs will convert to one share each upon vesting and vest 100% on the first anniversary of the grant. This is a compensation award — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-24; Form 4 filed: 2026-07-28 (timely relative to the two-business-day rule).
• Transaction type: Award (Code A) — 2,538 RSUs; price: N/A; total value: not specified.
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 — RSUs issued under the Haemonetics Amended & Restated 2019 Long‑Term Incentive Compensation Plan; vest 100% one year after grant. F2 — Each RSU equals a contingent right to one common share when vested.
• No indication of a 10b5-1 plan, gift, tax withholding event, or late filing noted.

Context
RSU grants are routine equity compensation for executives and directors. They do not result in immediate stock purchases or sales; shares (and any taxable event) typically occur when RSUs vest. Such awards are informative about compensation but are not by themselves a direct market signal of the insider’s short‑term view.